A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology
Importance: Blood biomarkers that reflect neurofibrillary tau burden, a defining hallmark of Alzheimer disease (AD), remain limited. Endogenously cleaved microtubule-binding region tau 243 (eMTBR-tau243) has shown promise when measured by mass spectrometry; a scalable immunoassay could broaden research access and support clinical evaluation. Objective: To determine whether plasma levels of eMTBR-tau measured by a novel immunoassay are associated with tau neurofibrillary tangle pathology defined by neuropathology and tau positron emission tomography (PET). Design, Setting, and Participants: This cross-sectional study included brain donors with antemortem plasma from 2 US autopsy cohorts, and individuals with plasma samples and tau PET from 2 imaging cohorts in Canada and Sweden, with visits between 2002 and 2025 depending on the cohort. Exposures: Plasma eMTBR-tau measured with an immunoassay and eMTBR-tau243 measured with mass spectrometry. Main Outcomes and Measures: Plasma eMTBR-tau levels across neuropathologic Braak neurofibrillary tangle stages (I-VI, ranging from tangles confined to the entorhinal region to widespread neocortical tangles) and tau-PET Braak stages (0-VI), expressed as fold changes. Correlations with regional tau-PET standardized uptake value ratios (SUVRs; higher values indicating more tau tangles), discrimination of regional tau-PET positivity (area under the curve [AUC]), and correlation with mass spectrometry-based eMTBR-tau243. Results: The study included 728 participants in 4 cohorts (median age by cohort, 71.0-83.5 years; 41.3%-56.6% female). In the 2 autopsy cohorts (n = 241 and n = 240), eMTBR-tau age- and sex-adjusted geometric means were 0.0021 pg/mL and 0.0040 pg/mL, respectively, at Braak stages I-II vs 0.107 pg/mL and 0.101 pg/mL at Braak stage VI (50.5-fold [95% CI, 26.3-97.0] and 25.2-fold [95% CI, 15.8-40.3] higher for stage VI vs stages I-II; P < .001 for both cohorts). In one imaging cohort (n = 99), compared with tau-PET Braak stage 0, eMTBR-tau levels were 11.0-fold (95% CI, 6.9-17.5) higher at stages III-IV and 59.9-fold (95% CI, 39.5-90.7) higher at stages V-VI. Among participants positive for amyloid-β (Aβ) in another imaging cohort (n = 50), the Spearman rank correlations for eMTBR-tau with tau-PET SUVRs were ρ = 0.52 (95% CI, 0.28-0.70) in Braak regions I-II, 0.76 (95% CI, 0.61-0.86) in regions III-IV, and 0.85 (95% CI, 0.75-0.91) in regions V-VI (all P < .001). Immunoassay and mass spectrometry measurements were strongly correlated (Spearman rank correlation, ρ = 0.93 in all participants [n = 108] and ρ = 0.96 in Aβ-positive participants [n = 54]) and discriminated tau-PET positivity similarly (n = 102; AUC range, 0.96-0.99 for the immunoassay and 0.97-0.99 for mass spectrometry). Conclusions and Relevance: A plasma eMTBR-tau immunoassay identified neocortical tau pathology in autopsy and tau-PET cohorts and correlated strongly with mass spectrometry measurements, a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced neurofibrillary tangle pathology.
Authors
- Tainá M. Marques (ORCID: https://orcid.org/0000-0001-6098-2817)
- Alireza Atri (ORCID: https://orcid.org/0000-0003-4405-6973)
- Paolo Vitali (ORCID: https://orcid.org/0000-0001-8953-1542)
- Randall John Bateman (ORCID: https://orcid.org/0000-0002-7729-1702)
- Sebastian Palmqvist (ORCID: https://orcid.org/0000-0002-9267-1930)
- Erik Stomrud (ORCID: https://orcid.org/0000-0002-0841-5580)
- Wagner Scheeren Brum (ORCID: https://orcid.org/0000-0002-9777-0559)
- Elizabeth Head
- Niklas Mattsson (ORCID: https://orcid.org/0000-0002-8885-7724)
- Craig E.L. Stark (ORCID: https://orcid.org/0000-0002-9334-8502)
- Antoine Leuzy (ORCID: https://orcid.org/0000-0003-4542-7879)
- Eric M. Reiman (ORCID: https://orcid.org/0000-0002-0705-3696)
- Arthur C. Macedo (ORCID: https://orcid.org/0000-0002-3957-0284)
- Geidy E. Serrano (ORCID: https://orcid.org/0000-0002-9527-2011)
- Tevy Chan (ORCID: https://orcid.org/0009-0001-9134-5949)
- Joshua D. Grill (ORCID: https://orcid.org/0000-0002-4215-7589)
- Jon Springett
- Thomas G. Beach (ORCID: https://orcid.org/0000-0003-3296-6128)
- Suzanne E. Schindler (ORCID: https://orcid.org/0000-0002-1680-1465)
- Shorena Janelidze (ORCID: https://orcid.org/0000-0003-2869-8378)
- Kanta Horie (ORCID: https://orcid.org/0000-0001-7736-2614)
- Marisa N. Denkinger (ORCID: https://orcid.org/0000-0002-3696-3795)
- Peter Harrison
- Lydia Trudel (ORCID: https://orcid.org/0009-0002-5593-7717)
- Pedro Rosa-Neto
- Kevin Wood
- Taraneh E Atri (ORCID: https://orcid.org/0009-0001-4492-2424)
- Serge Gauthier
- Nesrine Rahmouni
- Joseph Therriault
- Henrik Zetterberg
- William H. Yong
- Nicholas J. Ashton
- Claire Brooks
- Gleb Bezgin
- Oskar Hansson
- Jessica B. Langbaum
- Michael Turton
- Edwin S. Monuki
- Alpana Singh
- Seyyed Ali Hosseini
Institutions
- Montreal Neurological Institute and Hospital (CA)
- University of Wisconsin–Madison (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
- Lund University (SE)
- University of California, Irvine (US)
- Washington University in St. Louis (US)
- Douglas Mental Health University Institute (CA)
- Sahlgrenska University Hospital (SE)
- Southwestern Medical Center (US)
- UK Dementia Research Institute (GB)
- Skåne University Hospital (SE)
- Banner Sun Health Research Institute (US)
- Eisai (United States) (US)
- Centres Intégré Universitaires de Santé et de Services Sociaux (CA)
- Banner Alzheimer’s Institute (US)
- Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l’Île-de-Montréal (CA)
- Research Institute of the McGill University Health Centre (CA)
- McGill University Research Centre for Studies in Aging (CA)
- University College London (GB)
- Mass General Brigham (US)
- McGill University (CA)
- The University of Texas Southwestern Medical Center (US)
- University of Gothenburg (SE)
Publication Details
- Journal
- JAMA
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1001/jama.2026.25143
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00